A drug that recruits immune cells to fight an aggressive form of lymphoma that disproportionately affects minorities in the United States appears to be more effective than chemotherapy, according to Adrienne Phillips, M.D. Read more
Metastatic prostate cancer patients respond better to treatment when they switch to different drugs in the absence of an optimal initial response, according to Scott Tagawa, M.D. and Paraskevi Giannakakou, Ph.D. Read more
Ruben Niesvizky, M.D., comments on a study that tested a new drug combination (daratumumab+bortezomib+dexamethasone) to treat multiple myeloma Read more
Discussing re-staging scan results with oncologists—rather than other care-team members—may lead to a better understanding of late- or end-stage disease in patients with advanced cancers. Read more
The steroid dexamethasone could potentially deter the growth of a prostate cancer subtype that was previously thought to be difficult to treat with medications, according to research by David Rickman and Olivier Elemento. Read more
Scott T. Tagawa, M.D., M.S., discusses the antibody-drug conjugate IMMU-132 for the treatment of patients with metastatic platinum-resistant urothelial cancer. Read more